Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease

[1]  E. Silvestri,et al.  Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study , 2017, Clinical Rheumatology.

[2]  L. Punzi,et al.  A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study , 2016, Front. Pharmacol..

[3]  T. Hibi,et al.  Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study , 2016, Medicine.

[4]  E. Alpsoy.  Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions , 2016, The Journal of dermatology.

[5]  M. Galeazzi,et al.  New therapeutic solutions for Behçet’s syndrome , 2016, Expert opinion on investigational drugs.

[6]  A. Federico,et al.  Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. , 2016, The Israel Medical Association journal : IMAJ.

[7]  A. Gabrielli,et al.  Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile. , 2016, Current drug safety.

[8]  M. González-Gay,et al.  The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. , 2016, Clinical and experimental rheumatology.

[9]  M. Galeazzi,et al.  Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study , 2016, Clinical Rheumatology.

[10]  L. Cimino,et al.  Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study , 2016, Clinical Rheumatology.

[11]  I. Olivieri,et al.  Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study , 2016, Clinical Rheumatology.

[12]  G. Hatemi,et al.  Behçet's syndrome: a critical digest of the 2014-2015 literature. , 2015, Clinical and experimental rheumatology.

[13]  X. Mariette,et al.  Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. , 2015, Journal of autoimmunity.

[14]  M. Galeazzi,et al.  Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives , 2015, Mediators of inflammation.

[15]  T. Hibi,et al.  Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  A. Vitale,et al.  Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab , 2015, Clinical Rheumatology.

[17]  F. Romero-Bueno,et al.  Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. , 2014, Rheumatology.

[18]  M. Cordero-Coma,et al.  Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience , 2014, Mediators of inflammation.

[19]  F. Monti,et al.  A case of neuromyotonia in Behçet disease during TNF-α antagonist therapy , 2014, Neurological Sciences.

[20]  D. Ma,et al.  Etanercept in the Treatment of Intestinal Behcet’s Disease , 2014, Cell Biochemistry and Biophysics.

[21]  M. Galeazzi,et al.  Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series , 2014, Dermatology.

[22]  I. Olivieri,et al.  The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria , 2014 .

[23]  L. Punzi,et al.  Anakinra treatment in drug-resistant Behcet’s disease: a case series , 2015, Clinical Rheumatology.

[24]  A. Dick,et al.  Behçet Disease-associated Uveitis Successfully Treated with Golimumab , 2013, Ocular immunology and inflammation.

[25]  PhD Prof. Dr. R.H.A. Mohammed MD.  Etanercept therapy in Behçet’s disease , 2013, Zeitschrift für Rheumatologie.

[26]  P. Sfikakis,et al.  Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. , 2011, Seminars in arthritis and rheumatism.

[27]  I. Olivieri,et al.  Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. , 2011, Clinical and experimental rheumatology.

[28]  M. Galeazzi,et al.  Safety and Efficacy of Etanercept in Children with Juvenile-Onset Behcet's Disease , 2009, International journal of immunopathology and pharmacology.

[29]  A. Silman,et al.  EULAR recommendations for the management of Behçet disease , 2008, Annals of the rheumatic diseases.

[30]  J. Bamford,et al.  A patient with neuro-Behçet's disease is successfully treated with etanercept: Further evidence for the value of TNFα blockade , 2007, Clinical Neurology and Neurosurgery.

[31]  C. Goldenstein-Schainberg,et al.  Cross-cultural adaptation of the Behçet’s Disease Current Activity Form (BDCAF) to Brazilian Portuguese language , 2007, Clinical Rheumatology.

[32]  Y. Ozyazgan,et al.  Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. , 2005, The Journal of rheumatology.

[33]  A. Silman,et al.  [Criteria of diagnosis of Behcet's disease]. , 1975, La Tunisie medicale.